technetium-tc-99m-medronate and Hepatitis--Chronic

technetium-tc-99m-medronate has been researched along with Hepatitis--Chronic* in 1 studies

Other Studies

1 other study(ies) available for technetium-tc-99m-medronate and Hepatitis--Chronic

ArticleYear
Osteodystrophy in liver cirrhosis: detection and treatment evaluation using 99Tcm methylene diphosphonate bone scintigraphy.
    Clinical radiology, 1991, Volume: 43, Issue:1

    To investigate osteodystrophy in liver cirrhosis, 99Tcm MDP (methylene diphosphonate) bone scintigraphy was performed on 36 patients with liver cirrhosis. Abnormal lesions were detected in 17 out of 36 scans (47.2%). On the other hand, areas of increased uptake were uncommon in patients with chronic active hepatitis (1/11 cases). Plasma vitamin D3 fractions [25(OH)D3, 24.25(OH)2D3 and 1.25(OH)2D3] were decreased. Statistically significant depletion of 1.25(OH)2D3 was observed in cases with positive bone scintigraphy. 1 alpha(OH)D3 (1-2 micrograms/day) was administered for 6 months to nine patients having abnormal bone scans. Six of them showed improvement without any apparent side-effects. We conclude that hepatic cirrhotic osteodystrophy can be diagnosed positively by 99Tcm MDP bone scintigraphy and can be treated accordingly.

    Topics: Adult; Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cholecalciferol; Evaluation Studies as Topic; Female; Hepatitis, Chronic; Humans; Hydroxycholecalciferols; Liver Cirrhosis; Male; Middle Aged; Radionuclide Imaging; Ribs; Spine; Technetium Tc 99m Medronate

1991